Catherine L. Hough
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Catherine L. Hough has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Al Ozonoff
The Broad Institute of MIT and Harvard
3 shared publications - Albert C. Shaw
Yale School of Medicine, New Haven, Connecticut, USA
3 shared publications - Alison Deckhut Augustine
National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland, USA
3 shared publications - Bali Pulendran
Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, USA
3 shared publications - Bjoern Peters
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA
3 shared publications - Carolyn S. Calfee
UCSF, San Francisco, California, USA
3 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (7) , e1436
A Qualitative Multicenter Study of Participant Experiences With an App-Based Mindfulness Intervention (Lift 2) for Critical Illness Survivors
IMPORTANCE: Persistent physical and mental health symptoms are common among ICU survivors and pose barriers to recovery. A randomized clinical trial of an app-based mindfulness intervention (Lift) for ICU survivors suggested improvement in mental health symptoms; however, participants’ perceptions of the intervention and its influence on their recovery is unknown. OBJECTIVES: We sought to understand ICU survivors’ perspectives on how the app-based mindfulness intervention influenced their recovery and identify potential mechanisms by which it influenced their physical/mental health symptoms. DESIGN, SETTING, AND PARTICIPANTS: This is a preplanned qualitative study of participants in the Lift 2 clinical trial at three academic medical centers between 2019 and 2023. We performed semi-structured interviews (from March 2024 to June 2024) of adults who survived an ICU stay for acute cardiorespiratory failure and completed the 1-month mindfulness program ( n = 85), purposively sampling the twice-daily meditation group. ANALYSIS: We used a combined deductive/inductive approach to identify factors influencing the perceived effectiveness of the mindfulness intervention and general facilitators of recovery. RESULTS: Nineteen participants were enrolled, including six women (32%). Median age was 60 years (interquartile range, 43–66 yr). We identified themes related to participants’ perceptions of the intervention and its influence on their recovery, leveraging the Who-What-When-Where-Why-How framework to organize results. Themes included: a) participants’ receptiveness to mindfulness influenced their perceptions of its benefit (“who”); b) breathing exercises and mindfulness videos were considered the most useful content (“what”) given their positive impact on mind/body connection; c) participants described perceived reductions in dyspnea and hypertension (“why”) after using the app; d) the app-based intervention was feasible and easy to use (“how”); and e) integration of mindfulness with other rehabilitation techniques was synergistic and facilitated recovery (“where/when”). CONCLUSIONS: This qualitative study identifies potential mechanisms by which an app-based mindfulness intervention improved mental health and reduced physical symptom burden as perceived by ICU survivors. It also informs the development and implementation of future interventions to improve recovery from critical illness.
- 1 July 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (7) , e1436
Open AccessA Qualitative Multicenter Study of Participant Experiences With an App-Based Mindfulness Intervention (Lift 2) for Critical Illness Survivors
IMPORTANCE: Persistent physical and mental health symptoms are common among ICU survivors and pose barriers to recovery. A randomized clinical trial of an app-based mindfulness intervention (Lift) for ICU survivors suggested improvement in mental health symptoms; however, participants’ perceptions of the intervention and its influence on their recovery is unknown. OBJECTIVES: We sought to understand ICU survivors’ perspectives on how the app-based mindfulness intervention influenced their recovery and identify potential mechanisms by which it influenced their physical/mental health symptoms. DESIGN, SETTING, AND PARTICIPANTS: This is a preplanned qualitative study of participants in the Lift 2 clinical trial at three academic medical centers between 2019 and 2023. We performed semi-structured interviews (from March 2024 to June 2024) of adults who survived an ICU stay for acute cardiorespiratory failure and completed the 1-month mindfulness program ( n = 85), purposively sampling the twice-daily meditation group. ANALYSIS: We used a combined deductive/inductive approach to identify factors influencing the perceived effectiveness of the mindfulness intervention and general facilitators of recovery. RESULTS: Nineteen participants were enrolled, including six women (32%). Median age was 60 years (interquartile range, 43–66 yr). We identified themes related to participants’ perceptions of the intervention and its influence on their recovery, leveraging the Who-What-When-Where-Why-How framework to organize results. Themes included: a) participants’ receptiveness to mindfulness influenced their perceptions of its benefit (“who”); b) breathing exercises and mindfulness videos were considered the most useful content (“what”) given their positive impact on mind/body connection; c) participants described perceived reductions in dyspnea and hypertension (“why”) after using the app; d) the app-based intervention was feasible and easy to use (“how”); and e) integration of mindfulness with other rehabilitation techniques was synergistic and facilitated recovery (“where/when”). CONCLUSIONS: This qualitative study identifies potential mechanisms by which an app-based mindfulness intervention improved mental health and reduced physical symptom burden as perceived by ICU survivors. It also informs the development and implementation of future interventions to improve recovery from critical illness.
- Open Access
- 30 May 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 166, 108359
Blueprint 2: A self-directed mobile adaptive coping skills intervention to improve psychological distress symptoms among cardiorespiratory failure survivors study protocol
- 30 May 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 166, 108359
Open AccessBlueprint 2: A self-directed mobile adaptive coping skills intervention to improve psychological distress symptoms among cardiorespiratory failure survivors study protocol
- Open Access
- 11 December 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (3)
Diurnal rhythm in chimeric antigen receptor T cell effectiveness in an observational study of 715 patients
BACKGROUND: Chimeric antigen receptor (CAR) T cells are a leading immunotherapy for refractory B cell malignancies; however, their effect is limited by toxicity and incomplete efficacy. Daily (circadian) rhythms in immune function may offer a lever to boost therapeutic success; however, their clinical relevance to CAR T cell therapy remains unknown. METHODS: We retrospectively analyzed CAR T cell survival and complications based on infusion time at 2 geographically distinct hospitals: Washington University School of Medicine in St. Louis, Missouri, USA (n = 384) and Oregon Health & Science University in Portland, Oregon, USA (n = 331) between January 2018 and March 2025. The primary outcome was 90-day overall survival (OS). Secondary outcomes included event-free survival (EFS), cytokine release syndrome (CRS), immune cell–associated neurotoxicity syndrome (ICANS), ICU admission, shock, respiratory failure, and infection. We quantified the independent relationship between infusion time and outcomes using multivariable mixed-effects logistic regression and time-to-event models, adjusting for patient, oncologic, and treatment characteristics. RESULTS: The therapeutic index of CAR-T cells inversely correlated with the timing of administration, with later infusions associated with lower effectiveness and more adverse outcomes. For each hour that CAR T cell treatment was delayed, the adjusted odds ratio (aOR) of 90-day mortality increased by 24% (aOR 0.76; 95% CI 0.64–0.88, P = 0.001), severe neurotoxicity by 17% ( P = 0.023), and mechanical ventilation by 27% ( P = 0.026). These temporal patterns were most pronounced in patients receiving CD19-targeting CAR T cell products. In contrast, we did not find an association between infusion time and severe CRS (aOR 0.99; 95% CI, 0.75–1.27; P = 0.92). CONCLUSION: Time of day is a potent and easily modifiable factor that could optimize CAR T cell clinical performance.
- 11 December 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (3)
Open AccessDiurnal rhythm in chimeric antigen receptor T cell effectiveness in an observational study of 715 patients
BACKGROUND: Chimeric antigen receptor (CAR) T cells are a leading immunotherapy for refractory B cell malignancies; however, their effect is limited by toxicity and incomplete efficacy. Daily (circadian) rhythms in immune function may offer a lever to boost therapeutic success; however, their clinical relevance to CAR T cell therapy remains unknown. METHODS: We retrospectively analyzed CAR T cell survival and complications based on infusion time at 2 geographically distinct hospitals: Washington University School of Medicine in St. Louis, Missouri, USA (n = 384) and Oregon Health & Science University in Portland, Oregon, USA (n = 331) between January 2018 and March 2025. The primary outcome was 90-day overall survival (OS). Secondary outcomes included event-free survival (EFS), cytokine release syndrome (CRS), immune cell–associated neurotoxicity syndrome (ICANS), ICU admission, shock, respiratory failure, and infection. We quantified the independent relationship between infusion time and outcomes using multivariable mixed-effects logistic regression and time-to-event models, adjusting for patient, oncologic, and treatment characteristics. RESULTS: The therapeutic index of CAR-T cells inversely correlated with the timing of administration, with later infusions associated with lower effectiveness and more adverse outcomes. For each hour that CAR T cell treatment was delayed, the adjusted odds ratio (aOR) of 90-day mortality increased by 24% (aOR 0.76; 95% CI 0.64–0.88, P = 0.001), severe neurotoxicity by 17% ( P = 0.023), and mechanical ventilation by 27% ( P = 0.026). These temporal patterns were most pronounced in patients receiving CD19-targeting CAR T cell products. In contrast, we did not find an association between infusion time and severe CRS (aOR 0.99; 95% CI, 0.75–1.27; P = 0.92). CONCLUSION: Time of day is a potent and easily modifiable factor that could optimize CAR T cell clinical performance.
- Open Access
- 28 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (21)
A multiomics recovery factor predicts long COVID in the IMPACC study
BACKGROUND: Following SARS-CoV-2 infection, approximately 10%–35% of patients with COVID-19 experience long COVID (LC), in which debilitating symptoms persist for at least 3 months. Elucidating the biologic underpinnings of LC could identify therapeutic opportunities. METHODS: We utilized machine learning methods on biologic analytes provided over 12 months after hospital discharge from more than 500 patients with COVID-19 in the IMPACC cohort to identify a multiomics “recovery factor,” trained on patient-reported physical function survey scores. Immune profiling data included PBMC transcriptomics, serum O-link and plasma proteomics, plasma metabolomics, and blood mass cytometry by time of flight (CyTOF) protein levels. Recovery factor scores were tested for association with LC, disease severity, clinical parameters, and immune subset frequencies. Enrichment analyses identified biologic pathways associated with recovery factor scores. RESULTS: Participants with LC had lower recovery factor scores compared with recovered participants. Recovery factor scores predicted LC as early as hospital admission, irrespective of acute COVID-19 severity. Biologic characterization revealed increased inflammatory mediators, elevated signatures of heme metabolism, and decreased androgenic steroids as predictive and ongoing biomarkers of LC. Lower recovery factor scores were associated with reduced lymphocyte and increased myeloid cell frequencies. The observed signatures are consistent with persistent inflammation driving anemia and stress erythropoiesis as major biologic underpinnings of LC. CONCLUSION: The multiomics recovery factor identifies patients at risk of LC early after SARS-CoV-2 infection and reveals LC biomarkers and potential treatment targets. TRIAL REGISTRATION: ClinicalTrials.gov NCT04378777. FUNDING: National Institute of Allergy and Infectious Diseases (NIAID), NIH (3U01AI167892-03S2, 3U01AI167892-01S2, 5R01AI135803-03, 5U19AI118608-04, 5U19AI128910-04, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI057229-18, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07S1, 3U19AI089992-09, 3U19AI128913-03, and 5T32DA018926-1, 3U19AI1289130, U19AI128913-04S1, R01AI122220); NIH (UM1TR004528); and National Science Foundation (NSF) (DMS2310836).
- 28 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (21)
Open AccessA multiomics recovery factor predicts long COVID in the IMPACC study
BACKGROUND: Following SARS-CoV-2 infection, approximately 10%–35% of patients with COVID-19 experience long COVID (LC), in which debilitating symptoms persist for at least 3 months. Elucidating the biologic underpinnings of LC could identify therapeutic opportunities. METHODS: We utilized machine learning methods on biologic analytes provided over 12 months after hospital discharge from more than 500 patients with COVID-19 in the IMPACC cohort to identify a multiomics “recovery factor,” trained on patient-reported physical function survey scores. Immune profiling data included PBMC transcriptomics, serum O-link and plasma proteomics, plasma metabolomics, and blood mass cytometry by time of flight (CyTOF) protein levels. Recovery factor scores were tested for association with LC, disease severity, clinical parameters, and immune subset frequencies. Enrichment analyses identified biologic pathways associated with recovery factor scores. RESULTS: Participants with LC had lower recovery factor scores compared with recovered participants. Recovery factor scores predicted LC as early as hospital admission, irrespective of acute COVID-19 severity. Biologic characterization revealed increased inflammatory mediators, elevated signatures of heme metabolism, and decreased androgenic steroids as predictive and ongoing biomarkers of LC. Lower recovery factor scores were associated with reduced lymphocyte and increased myeloid cell frequencies. The observed signatures are consistent with persistent inflammation driving anemia and stress erythropoiesis as major biologic underpinnings of LC. CONCLUSION: The multiomics recovery factor identifies patients at risk of LC early after SARS-CoV-2 infection and reveals LC biomarkers and potential treatment targets. TRIAL REGISTRATION: ClinicalTrials.gov NCT04378777. FUNDING: National Institute of Allergy and Infectious Diseases (NIAID), NIH (3U01AI167892-03S2, 3U01AI167892-01S2, 5R01AI135803-03, 5U19AI118608-04, 5U19AI128910-04, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI057229-18, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07S1, 3U19AI089992-09, 3U19AI128913-03, and 5T32DA018926-1, 3U19AI1289130, U19AI128913-04S1, R01AI122220); NIH (UM1TR004528); and National Science Foundation (NSF) (DMS2310836).
- Open Access
- 3 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (15)
MICBG406A polymorphism reduces risk of mechanical ventilation and death during viral acute lung injury
MHC class I polypeptide-related sequence B (MICB) is a ligand for NKG2D. We have shown NK cells are central to lung transplant acute lung injury (ALI) via NKG2D activation, and increased MICB in bronchoalveolar lavage predicts ALI severity. Separately, we found a MICB polymorphism ( MICB G406A ) is associated with decreased ALI risk. We hypothesized this polymorphism would protect against severe SARS-CoV-2 respiratory disease. We analyzed 1,036 patients hospitalized with SARS-CoV-2 infection from IMPACC. Associations between MICB G406A and outcomes were determined by linear regression or Cox proportional hazards models. We also measured immune profiles of peripheral blood and the upper and lower airway. We identified 560 major allele homozygous patients, and 426 and 50 with 1 or 2 copies of the variant allele, respectively. MICB G406A conferred reduced odds of severe COVID-19. MICB G406A homozygous participants demonstrated 34% reduced cumulative odds for mechanical ventilation or death and 43% reduced risk for mortality. Patients with MICB G406A variant alleles had reduced soluble inflammatory mediators and differential regulation of multiple immune pathways. These findings demonstrate a potentially novel association between increasing MICB G406A variant allele copies and reduced COVID-19 severity, independent of SARS-CoV-2 viral burden and humoral immunity, suggesting the NKG2D-ligand pathway as an intervention target.
- 3 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (15)
Open AccessMICBG406A polymorphism reduces risk of mechanical ventilation and death during viral acute lung injury
MHC class I polypeptide-related sequence B (MICB) is a ligand for NKG2D. We have shown NK cells are central to lung transplant acute lung injury (ALI) via NKG2D activation, and increased MICB in bronchoalveolar lavage predicts ALI severity. Separately, we found a MICB polymorphism ( MICB G406A ) is associated with decreased ALI risk. We hypothesized this polymorphism would protect against severe SARS-CoV-2 respiratory disease. We analyzed 1,036 patients hospitalized with SARS-CoV-2 infection from IMPACC. Associations between MICB G406A and outcomes were determined by linear regression or Cox proportional hazards models. We also measured immune profiles of peripheral blood and the upper and lower airway. We identified 560 major allele homozygous patients, and 426 and 50 with 1 or 2 copies of the variant allele, respectively. MICB G406A conferred reduced odds of severe COVID-19. MICB G406A homozygous participants demonstrated 34% reduced cumulative odds for mechanical ventilation or death and 43% reduced risk for mortality. Patients with MICB G406A variant alleles had reduced soluble inflammatory mediators and differential regulation of multiple immune pathways. These findings demonstrate a potentially novel association between increasing MICB G406A variant allele copies and reduced COVID-19 severity, independent of SARS-CoV-2 viral burden and humoral immunity, suggesting the NKG2D-ligand pathway as an intervention target.
- Open Access
- 22 May 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (13)
High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19
CD16A is an activating Fc receptor on NK cells that mediates antibody-dependent cellular cytotoxicity (ADCC), a key mechanism in antiviral immunity. However, the role of NK cell–mediated ADCC in SARS-CoV-2 infection remains unclear, particularly whether it limits viral spread and disease severity or contributes to the immunopathogenesis of COVID-19. We hypothesized that the high-affinity CD16A V176 polymorphism influences these outcomes. Using an in vitro reporter system, we demonstrated that CD16A V176 is a more potent and sensitive activator than the common CD16A F176 allele. To assess its clinical relevance, we analyzed 1,027 patients hospitalized with COVID-19 from the Immunophenotyping Assessment in a COVID-19 cohort (IMPACC), a comprehensive longitudinal dataset with extensive transcriptomic, proteomic, and clinical data. The high-affinity CD16A V176 allele was associated with a significantly reduced risk of ICU admission, mechanical ventilation, and severe disease trajectories. Lower anti–SARS-CoV-2 IgG titers were correlated to CD16A V176 ; however, there was no difference in viral load across CD16A genotypes. Proteomic analysis revealed that participants homozygous for CD16A V176 had lower levels of inflammatory mediators. These findings suggest that CD16A V176 enhances early NK cell–mediated immune responses, limiting severe respiratory complications in COVID-19. This study identifies a protective genetic factor against severe COVID-19, informing future host-directed therapeutic strategies.
- 22 May 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (13)
Open AccessHigh-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19
CD16A is an activating Fc receptor on NK cells that mediates antibody-dependent cellular cytotoxicity (ADCC), a key mechanism in antiviral immunity. However, the role of NK cell–mediated ADCC in SARS-CoV-2 infection remains unclear, particularly whether it limits viral spread and disease severity or contributes to the immunopathogenesis of COVID-19. We hypothesized that the high-affinity CD16A V176 polymorphism influences these outcomes. Using an in vitro reporter system, we demonstrated that CD16A V176 is a more potent and sensitive activator than the common CD16A F176 allele. To assess its clinical relevance, we analyzed 1,027 patients hospitalized with COVID-19 from the Immunophenotyping Assessment in a COVID-19 cohort (IMPACC), a comprehensive longitudinal dataset with extensive transcriptomic, proteomic, and clinical data. The high-affinity CD16A V176 allele was associated with a significantly reduced risk of ICU admission, mechanical ventilation, and severe disease trajectories. Lower anti–SARS-CoV-2 IgG titers were correlated to CD16A V176 ; however, there was no difference in viral load across CD16A genotypes. Proteomic analysis revealed that participants homozygous for CD16A V176 had lower levels of inflammatory mediators. These findings suggest that CD16A V176 enhances early NK cell–mediated immune responses, limiting severe respiratory complications in COVID-19. This study identifies a protective genetic factor against severe COVID-19, informing future host-directed therapeutic strategies.
- 13 January 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (1) , e1193
Representation of Hispanic Patients in Clinical Trials for Respiratory Failure: A Systematic Review
OBJECTIVES: Hispanic individuals comprise one-fifth of the U.S. population and Hispanic patients with acute hypoxemic respiratory failure (AHRF) experience higher odds of death compared with non-Hispanic White patients. Representation of Hispanic patients in clinical trials for respiratory failure is critical to address this inequity. We conducted a systematic review to examine the inclusion of Hispanic patients in randomized controlled trials for AHRF and assessed language as a potential barrier to enrollment. DATA SOURCES: National Library of Medicine PubMed, Elsevier Embase, and Cochrane Central Register of Controlled Trials databases through January 2024. STUDY SELECTION: Randomized controlled trials assessing AHRF interventions enrolling U.S. patients receiving mechanical ventilation, noninvasive mechanical ventilation, or high-flow nasal cannula were included. The systematic review was registered prospectively through PROSPERO (CRD42023437828). DATA EXTRACTION: Two authors independently screened studies and extracted data for each included study. DATA SYNTHESIS: Ninety-four trials published from 1975 to 2023 were included; 33.0% (n = 31) of studies reported ethnicity, and 11.2% of participants in studies reporting race or ethnicity (1,320/11,780) were identified as Hispanic. The proportion of Hispanic-identified participants was significantly lower than the U.S. Hispanic population from 1996 to 2019 (p < 0.01). Starting in 2020, the proportion of Hispanic-identified participants was significantly higher than the U.S. population (27.8% vs. 19.1%; p < 0.01). Two studies (4.9%) reporting race or ethnicity excluded non-English speaking participants; the remainder did not specify language requirements for enrollment. CONCLUSIONS: Hispanic-identified individuals were underrepresented in trials for AHRF until 2020 when Hispanic patient representation increased during COVID-19. Exclusion of participants who do not speak English may represent a barrier to trial enrollment.
- 13 January 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (1) , e1193
Representation of Hispanic Patients in Clinical Trials for Respiratory Failure: A Systematic Review
OBJECTIVES: Hispanic individuals comprise one-fifth of the U.S. population and Hispanic patients with acute hypoxemic respiratory failure (AHRF) experience higher odds of death compared with non-Hispanic White patients. Representation of Hispanic patients in clinical trials for respiratory failure is critical to address this inequity. We conducted a systematic review to examine the inclusion of Hispanic patients in randomized controlled trials for AHRF and assessed language as a potential barrier to enrollment. DATA SOURCES: National Library of Medicine PubMed, Elsevier Embase, and Cochrane Central Register of Controlled Trials databases through January 2024. STUDY SELECTION: Randomized controlled trials assessing AHRF interventions enrolling U.S. patients receiving mechanical ventilation, noninvasive mechanical ventilation, or high-flow nasal cannula were included. The systematic review was registered prospectively through PROSPERO (CRD42023437828). DATA EXTRACTION: Two authors independently screened studies and extracted data for each included study. DATA SYNTHESIS: Ninety-four trials published from 1975 to 2023 were included; 33.0% (n = 31) of studies reported ethnicity, and 11.2% of participants in studies reporting race or ethnicity (1,320/11,780) were identified as Hispanic. The proportion of Hispanic-identified participants was significantly lower than the U.S. Hispanic population from 1996 to 2019 (p < 0.01). Starting in 2020, the proportion of Hispanic-identified participants was significantly higher than the U.S. population (27.8% vs. 19.1%; p < 0.01). Two studies (4.9%) reporting race or ethnicity excluded non-English speaking participants; the remainder did not specify language requirements for enrollment. CONCLUSIONS: Hispanic-identified individuals were underrepresented in trials for AHRF until 2020 when Hispanic patient representation increased during COVID-19. Exclusion of participants who do not speak English may represent a barrier to trial enrollment.
- 1 October 2023
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 29 (5) , 470-471
Editorial: All together now: improving critical care outcomes through multidisciplinary and interprofessional teamwork
- 1 October 2023
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 29 (5) , 470-471
Editorial: All together now: improving critical care outcomes through multidisciplinary and interprofessional teamwork
- Open Access
- 24 March 2021
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 16 (1) , 1-6
Should the CIWA-Ar be the standard monitoring strategy for alcohol withdrawal syndrome in the intensive care unit?
Background: The Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) is commonly used in hospitals to titrate medications for alcohol withdrawal syndrome (AWS), but may be difficult to apply to intensive care unit (ICU) patients who are too sick or otherwise unable to communicate. Objectives: To evaluate the frequency of CIWA-Ar monitoring among ICU patients with AWS and variation in CIWA-Ar monitoring across patient demographic and clinical characteristics. Methods: The study included all adults admitted to an ICU in 2017 after treatment for AWS in the Emergency Department of an academic hospital that standardly uses the CIWA-Ar to assess AWS severity and response to treatment. Demographic and clinical data, including Richmond Agitation-Sedation Scale (RASS) assessments (an alternative measure of agitation/sedation), were obtained via chart review. Associations between patient characteristics and CIWA-Ar monitoring were tested using logistic regression. Results: After treatment for AWS, only 56% (n = 54/97) of ICU patients were evaluated using the CIWA-Ar; 94% of patients had a documented RASS assessment (n = 91/97). Patients were significantly less likely to receive CIWA-Ar monitoring if they were intubated or identified as Black. Conclusions: CIWA-Ar monitoring was used inconsistently in ICU patients with AWS and completed less often in those who were intubated or identified as Black. These hypothesis-generating findings raise questions about the utility of the CIWA-Ar in ICU settings. Future studies should assess alternative measures for titrating AWS medications in the ICU that do not require verbal responses from patients and further explore the association of race with AWS monitoring.
- 24 March 2021
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 16 (1) , 1-6
Open AccessShould the CIWA-Ar be the standard monitoring strategy for alcohol withdrawal syndrome in the intensive care unit?
Background: The Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) is commonly used in hospitals to titrate medications for alcohol withdrawal syndrome (AWS), but may be difficult to apply to intensive care unit (ICU) patients who are too sick or otherwise unable to communicate. Objectives: To evaluate the frequency of CIWA-Ar monitoring among ICU patients with AWS and variation in CIWA-Ar monitoring across patient demographic and clinical characteristics. Methods: The study included all adults admitted to an ICU in 2017 after treatment for AWS in the Emergency Department of an academic hospital that standardly uses the CIWA-Ar to assess AWS severity and response to treatment. Demographic and clinical data, including Richmond Agitation-Sedation Scale (RASS) assessments (an alternative measure of agitation/sedation), were obtained via chart review. Associations between patient characteristics and CIWA-Ar monitoring were tested using logistic regression. Results: After treatment for AWS, only 56% (n = 54/97) of ICU patients were evaluated using the CIWA-Ar; 94% of patients had a documented RASS assessment (n = 91/97). Patients were significantly less likely to receive CIWA-Ar monitoring if they were intubated or identified as Black. Conclusions: CIWA-Ar monitoring was used inconsistently in ICU patients with AWS and completed less often in those who were intubated or identified as Black. These hypothesis-generating findings raise questions about the utility of the CIWA-Ar in ICU settings. Future studies should assess alternative measures for titrating AWS medications in the ICU that do not require verbal responses from patients and further explore the association of race with AWS monitoring.
- 1 September 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 96, 106119
Optimizing a self-directed mobile mindfulness intervention for improving cardiorespiratory failure survivors' psychological distress (LIFT2): Design and rationale of a randomized factorial experimental clinical trial
- 1 September 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 96, 106119
Optimizing a self-directed mobile mindfulness intervention for improving cardiorespiratory failure survivors' psychological distress (LIFT2): Design and rationale of a randomized factorial experimental clinical trial